Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Mugen1996on Mar 26, 2008 7:10pm
152 Views
Post# 14841036

RE: AGM review

RE: AGM reviewI was also in the attendance this morning, reviews from Simon and Inforcash are pretty accurate! I was quite surprised to see that we were only around 75 in the room! The management presentation was a recap of all we already know, including a couple on intresting slides: PP subscribers % and the 2008 schedule. TH plans to attend to 3 major conferences in 2008: - Endo in June (Presenting results for PIIIb) - ???? in August (Presenting Q0L for 52 weeks) - ???? in November (Presenting recap or both PIII trials) Serono's appeal was turn down last January. I would like to find the blog that Rosconi was refering to. Someone asked about the recent SP decline. He wanted to know if the decline was more related to fear surrending the January PR than the recent market conditions. Pommier and Rosconi looked at each other and seemed not very pleased to answer this question. It was pretty obvious that they would pointed out the market conditions...TH did better than the Healthcare maket during that period...ZZzzzz Something that sounded funny to my hears. Rosconi was talking about the multiple possible options second indication, then he said he would like to do them all at the same time, but we are not yet Pfizer!!! (Moneywise of course Andrea Gilpin told me there was less people than last year! Quite surprising Coffee was good... Food was ok I'm done!
Bullboard Posts